Wu Yanheng, Chen Mingshui, Wu Peihong, Chen Chen, Xu Zhi Ping, Gu Wenyi
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.
Laboratory of Immuno-Oncology, Department of Medical Oncology, Fujian Provincial Cancer Hospital &Institute, Fuzhou, China.
Clin Exp Pharmacol Physiol. 2017 May;44(5):602-604. doi: 10.1111/1440-1681.12732.
Here we report the expression of programmed cell death ligand 1/2 (PD-L1/L2) in breast and colon cancer stem cells (CSCs). The stemness of these cells was confirmed by their surface markers. Using flow cytometry analysis we demonstrated that PD-L1 expression was higher in CSCs of both cancers compared to non-stem like cancer cells. Consistent with this, detection of cellular PD-L1 proteins by western blot assay also showed increased PD-L1 protein in CSCs. In contrast, only trace amounts of PD-L2 were detected in CSCs of both cancers. Our results suggest that breast and colon cancers may be sensitive to PD1/PD-L1 immunotherapy and thus warrant further investigations of CSC targeted PD1/PD-L1 therapy.
在此，我们报告程序性细胞死亡配体1/2（PD-L1/L2）在乳腺癌和结肠癌干细胞（CSC）中的表达情况。这些细胞的干性通过其表面标志物得以证实。利用流式细胞术分析，我们证明与非干细胞样癌细胞相比，两种癌症的CSC中PD-L1表达更高。与此一致的是，通过蛋白质印迹分析检测细胞PD-L1蛋白也显示CSC中PD-L1蛋白增加。相比之下，在两种癌症的CSC中仅检测到微量的PD-L2。我们的结果表明，乳腺癌和结肠癌可能对PD1/PD-L1免疫疗法敏感，因此有必要进一步研究针对CSC的PD1/PD-L1疗法。
